Speaker(s): 
Samantha Kunkel, PharmD, BCACP, RPH, Geisinger Ambulatory Clinical Pharmacist, Medication Therapy Disease Management has nothing to disclose.

Moderator(s): 
Angela Esherick, RDN, LDN, CDCES, Geisinger Nutrition Services has nothing to disclose.

Learning Objectives: 
At the conclusion of this session, the participant should be able to: 

•    Recognize SGLT2 inhibitors 
•    Define mechanism of SGLT2 inhibitors 
•    Identify side effects of SGLT2 inhibitors 
•    Discuss place in therapy for Diabetes Mellitus, Chronic Kidney Disease, and Heart Failure 
•    Describe renal dose adjustments 
•    Discuss renal benefits of SGLT2i

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Stacy Coolbaugh, MBA, RDN, LDN; Angela Esherick, RDN, LDN, CDCES; Adriene Zook, PharmD, RPH, Dan Huston, DNP, RN, BC-ADM, and Angela Zammit have no identified disclosures. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 
This presentation/content is HIPPA compliant.